Selected research
Industry Research
Hydromorphone Industry Research Report 2026
Market perspective
The global Hydromorphone market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hydromorphone is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hydromorphone is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hydromorphone is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hydromorphone include Teva Pharmaceuticals, Johnson & Johnson, Novartis, Mylan, Pfizer, Fresenius, Watson Laboratories, Stada Arzneimittel and Purdue Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hydromorphone market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hydromorphone Market by Company
Teva Pharmaceuticals
Johnson & Johnson
Novartis
Mylan
Pfizer
Fresenius
Watson Laboratories
Stada Arzneimittel
Purdue Pharma
Mundipharma
Mallinckrodt
Lannett
KV Pharmaceutical
Barr Pharmaceuticals
Apotex
Akorn
Hydromorphone Segment by Type
Oral
Injection
Hydromorphone Segment by Application
Hospital
Drug Store
Hydromorphone Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hydromorphone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hydromorphone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hydromorphone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hydromorphone manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hydromorphone by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hydromorphone in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Drug Store
Companies covered
- Teva Pharmaceuticals
- Johnson & Johnson
- Novartis
- Mylan
- Pfizer
- Fresenius
- Watson Laboratories
- Stada Arzneimittel
- Purdue Pharma
- Mundipharma
- Mallinckrodt
- Lannett
- KV Pharmaceutical
- Barr Pharmaceuticals
- Apotex
- Akorn
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hydromorphone Market Size (2021-2032)
- 2.2.2 Global Hydromorphone Sales (2021-2032)
- 2.2.3 Global Hydromorphone Market Average Price (2021-2032)
- 2.3 Hydromorphone by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injection
- 2.4 Hydromorphone by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Drug Store
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hydromorphone Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hydromorphone Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Hydromorphone Revenue of Manufacturers (2021-2026)
- 3.4 Global Hydromorphone Average Price by Manufacturers (2021-2026)
- 3.5 Global Hydromorphone Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hydromorphone, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hydromorphone, Product Type & Application
- 3.8 Global Manufacturers of Hydromorphone, Established Date
- 3.9 Global Hydromorphone Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceuticals
- 4.1.1 Teva Pharmaceuticals Company Information
- 4.1.2 Teva Pharmaceuticals Business Overview
- 4.1.3 Teva Pharmaceuticals Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceuticals Hydromorphone Product Portfolio
- 4.1.5 Teva Pharmaceuticals Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Hydromorphone Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Hydromorphone Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Hydromorphone Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Hydromorphone Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Fresenius
- 4.6.1 Fresenius Company Information
- 4.6.2 Fresenius Business Overview
- 4.6.3 Fresenius Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Fresenius Hydromorphone Product Portfolio
- 4.6.5 Fresenius Recent Developments
- 4.7 Watson Laboratories
- 4.7.1 Watson Laboratories Company Information
- 4.7.2 Watson Laboratories Business Overview
- 4.7.3 Watson Laboratories Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Watson Laboratories Hydromorphone Product Portfolio
- 4.7.5 Watson Laboratories Recent Developments
- 4.8 Stada Arzneimittel
- 4.8.1 Stada Arzneimittel Company Information
- 4.8.2 Stada Arzneimittel Business Overview
- 4.8.3 Stada Arzneimittel Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Stada Arzneimittel Hydromorphone Product Portfolio
- 4.8.5 Stada Arzneimittel Recent Developments
- 4.9 Purdue Pharma
- 4.9.1 Purdue Pharma Company Information
- 4.9.2 Purdue Pharma Business Overview
- 4.9.3 Purdue Pharma Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Purdue Pharma Hydromorphone Product Portfolio
- 4.9.5 Purdue Pharma Recent Developments
- 4.10 Mundipharma
- 4.10.1 Mundipharma Company Information
- 4.10.2 Mundipharma Business Overview
- 4.10.3 Mundipharma Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mundipharma Hydromorphone Product Portfolio
- 4.10.5 Mundipharma Recent Developments
- 4.11 Mallinckrodt
- 4.11.1 Mallinckrodt Company Information
- 4.11.2 Mallinckrodt Business Overview
- 4.11.3 Mallinckrodt Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Mallinckrodt Hydromorphone Product Portfolio
- 4.11.5 Mallinckrodt Recent Developments
- 4.12 Lannett
- 4.12.1 Lannett Company Information
- 4.12.2 Lannett Business Overview
- 4.12.3 Lannett Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Lannett Hydromorphone Product Portfolio
- 4.12.5 Lannett Recent Developments
- 4.13 KV Pharmaceutical
- 4.13.1 KV Pharmaceutical Company Information
- 4.13.2 KV Pharmaceutical Business Overview
- 4.13.3 KV Pharmaceutical Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 KV Pharmaceutical Hydromorphone Product Portfolio
- 4.13.5 KV Pharmaceutical Recent Developments
- 4.14 Barr Pharmaceuticals
- 4.14.1 Barr Pharmaceuticals Company Information
- 4.14.2 Barr Pharmaceuticals Business Overview
- 4.14.3 Barr Pharmaceuticals Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Barr Pharmaceuticals Hydromorphone Product Portfolio
- 4.14.5 Barr Pharmaceuticals Recent Developments
- 4.15 Apotex
- 4.15.1 Apotex Company Information
- 4.15.2 Apotex Business Overview
- 4.15.3 Apotex Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Apotex Hydromorphone Product Portfolio
- 4.15.5 Apotex Recent Developments
- 4.16 Akorn
- 4.16.1 Akorn Company Information
- 4.16.2 Akorn Business Overview
- 4.16.3 Akorn Hydromorphone Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Akorn Hydromorphone Product Portfolio
- 4.16.5 Akorn Recent Developments
5 Global Hydromorphone Market Scenario by Region
- 5.1 Global Hydromorphone Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hydromorphone Sales by Region: 2021-2032
- 5.2.1 Global Hydromorphone Sales by Region: 2021-2026
- 5.2.2 Global Hydromorphone Sales by Region: 2027-2032
- 5.3 Global Hydromorphone Revenue by Region: 2021-2032
- 5.3.1 Global Hydromorphone Revenue by Region: 2021-2026
- 5.3.2 Global Hydromorphone Revenue by Region: 2027-2032
- 5.4 North America Hydromorphone Market Facts & Figures by Country
- 5.4.1 North America Hydromorphone Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hydromorphone Sales by Country (2021-2032)
- 5.4.3 North America Hydromorphone Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Hydromorphone Market Facts & Figures by Country
- 5.5.1 Europe Hydromorphone Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hydromorphone Sales by Country (2021-2032)
- 5.5.3 Europe Hydromorphone Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Hydromorphone Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hydromorphone Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hydromorphone Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hydromorphone Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hydromorphone Market Facts & Figures by Country
- 5.7.1 South America Hydromorphone Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hydromorphone Sales by Country (2021-2032)
- 5.7.3 South America Hydromorphone Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Hydromorphone Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hydromorphone Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hydromorphone Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hydromorphone Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Hydromorphone Sales by Type (2021-2032)
- 6.1.1 Global Hydromorphone Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Hydromorphone Sales Market Share by Type (2021-2032)
- 6.2 Global Hydromorphone Revenue by Type (2021-2032)
- 6.2.1 Global Hydromorphone Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hydromorphone Revenue Market Share by Type (2021-2032)
- 6.3 Global Hydromorphone Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hydromorphone Sales by Application (2021-2032)
- 7.1.1 Global Hydromorphone Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Hydromorphone Sales Market Share by Application (2021-2032)
- 7.2 Global Hydromorphone Revenue by Application (2021-2032)
- 7.2.1 Global Hydromorphone Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hydromorphone Revenue Market Share by Application (2021-2032)
- 7.3 Global Hydromorphone Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hydromorphone Value Chain Analysis
- 8.1.1 Hydromorphone Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hydromorphone Production Mode & Process
- 8.2 Hydromorphone Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hydromorphone Distributors
- 8.2.3 Hydromorphone Customers
9 Global Hydromorphone Analyzing Market Dynamics
- 9.1 Hydromorphone Industry Trends
- 9.2 Hydromorphone Industry Drivers
- 9.3 Hydromorphone Industry Opportunities and Challenges
- 9.4 Hydromorphone Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst